The deal has been reported to be worth US$36 million
A manufacturing facility in Suzhou, China has been purchased by Fosun Pharmaceuticals from GSK. The deal has been reported to be worth US$36 million, according to a company state.
The new owners of the facility west of Shanghai said that the plant produced a revenue of $94.4m in 2018.
The deal will also allow YaoPharma, Fosun's Chongqing unit, to acquire all production facilities and authorisations for the GSK plant's chronic hepatitis B drug lamivudine.
The news of this sale comes as GSK announced the opening of its new API continuous manufacturing facility in Singapore. This will be a big shift in manufacturing focus in the Asian region for the pharma giant.
